Wayman L L, Larsson L I, Maus T L, Brubaker R F
Mayo Medical School, Rochester, Minn., USA.
Arch Ophthalmol. 1998 Nov;116(11):1438-40. doi: 10.1001/archopht.116.11.1438.
To determine the additive effect on aqueous humor flow of short-term dorzolamide treatment in patients with glaucoma receiving long-term treatment with timolol.
Thirty-nine patients with glaucoma, 19 at Mayo Clinic, Rochester, Minn, and 20 at the University of Uppsala, Uppsala, Sweden, who had been receiving timolol treatment in both eyes for at least 1 year were studied. Aqueous flow was measured with fluorophotometry and intraocular pressure with tonometry. The effect of dorzolamide was compared with placebo when added to the long-term treatment regimen with timolol.
Dorzolamide reduced aqueous humor flow by 24% +/- 11% (mean +/- SD). The intraocular pressure as compared with placebo in the US cohort was reduced by 10% +/- 6% and in the Swedish cohort by 18% +/- 9%.
Dorzolamide, a carbonic anhydrase inhibitor, has additive effects as an ocular hypotensive agent with timolol, a beta-adrenergic antagonist, even though both drugs are suppressors of aqueous humor flow. Dorzolamide's effect on flow in these patients is the same as reported previously in normal subjects who are not taking a beta-adrenergic antagonist.
确定在接受噻吗洛尔长期治疗的青光眼患者中，短期使用多佐胺治疗对房水引流的附加作用。
对39例青光眼患者进行了研究，其中19例来自明尼苏达州罗切斯特市的梅奥诊所，20例来自瑞典乌普萨拉市的乌普萨拉大学，这些患者双眼接受噻吗洛尔治疗至少1年。采用荧光光度法测量房水引流，用眼压计测量眼压。将多佐胺添加到噻吗洛尔长期治疗方案中时，比较其与安慰剂的效果。
多佐胺使房水引流减少24%±11%（均值±标准差）。在美国队列中，与安慰剂相比眼压降低了10%±6%，在瑞典队列中降低了18%±9%。
碳酸酐酶抑制剂多佐胺与β-肾上腺素能拮抗剂噻吗洛尔联合作为降眼压药物具有附加作用，尽管这两种药物均抑制房水引流。多佐胺对这些患者房水引流的作用与先前在未服用β-肾上腺素能拮抗剂的正常受试者中所报道的相同。
